Risks and Recommendations for Long-Term Low-Dose Benzodiazepine Use

Introduction to Risks

Long-term low-dose benzodiazepine use is generally not recommended due to risks of dependence, cognitive impairment, and withdrawal symptoms, even at therapeutic doses, as recommended by the American Academy of Sleep Medicine 1, 2

Regular use of benzodiazepines can lead to tolerance, addiction, depression, and cognitive impairment, even at low doses, affecting patients with anxiety or insomnia 2
Approximately 10% of patients may experience paradoxical agitation with benzodiazepine treatment, which can be a concern for patients with a history of anxiety or mood disorders 2

Benzodiazepines not specifically approved for insomnia (e.g., lorazepam, clonazepam) might be considered if the duration of action is appropriate for the patient's presentation, according to the American Academy of Sleep Medicine 1
Short-acting benzodiazepines with shorter half-lives are generally preferred to minimize risk of adverse effects, as recommended by the American Academy of Family Physicians 2
In elderly patients, those with advanced liver disease, or debilitating conditions, higher risk of falls and cognitive impairment is common, highlighting the need for caution and close monitoring 3
Benzodiazepines are not recommended during pregnancy or nursing, due to potential risks to the fetus or baby, as advised by the American Academy of Sleep Medicine 1

For chronic insomnia, cognitive behavioral therapy for insomnia (CBT-I) should be considered as first-line treatment, as recommended by the American College of Physicians 3
For insomnia, consider non-benzodiazepine options such as melatonin receptor agonists (e.g., ramelteon), low-dose doxepin (3-6 mg), or non-benzodiazepine BZRAs (e.g., zolpidem, zaleplon, eszopiclone) at lowest effective doses for shortest duration, as suggested by the American Academy of Sleep Medicine and the American College of Physicians 1, 3

Approximately 50% of patients prescribed benzodiazepines continue them for at least 12 months, despite recommendations against this practice, with higher risk of dependence associated with doses greater than 4 mg/day, treatment duration exceeding 12 weeks, history of substance use disorders, female gender, and age 45-74 years, as well as higher levels of socioeconomic deprivation 4
Concurrent use of benzodiazepines with opioids increases the risk of respiratory depression 5, 6

The American Heart Association, as published in Circulation, recommends avoiding concurrent use of benzodiazepines with opioids due to increased risk of respiratory depression 5, 6

The VA/DoD guidelines advise against prescribing benzodiazepines for chronic insomnia disorder because the harms (dependence, falls, cognitive impairment in older adults, and hypoventilation in patients with respiratory disease) substantially outweigh any benefits. 7
Clinical trials of benzodiazepines for insomnia have generally limited treatment periods to no more than 4 weeks, reinforcing the recommendation for short‑term use only. 8

Cognitive Behavioral Therapy for Insomnia (CBT‑I) should be the initial intervention; it yields comparable short‑term outcomes (2–4 weeks) to benzodiazepines but demonstrates superior long‑term effectiveness. 9

Benzodiazepines are not recommended for chronic insomnia as ongoing therapy because safety data beyond brief courses are lacking and longer use is associated with increased risk. 9
If medication is required, non‑benzodiazepine agents (e.g., low‑dose doxepin, zolpidem, zaleplon, eszopiclone) should be prescribed at the lowest effective dose and for the shortest possible duration. 9